Why Novo Nordisk Stock Is Down Again Today

Key Points

• Novo Nordisk stock missed earnings a week ago and warned of slowing growth.

• Competition from drug compounding firms and from rival Eli Lilly is eating into Novo's market share.

• The stock keeps getting cheaper, but its growth rate and dividend yield remain good.

• 10 stocks we like better than Novo Nordisk ›

Shares of Novo Nordisk (NYSE: NVO), the Danish pharmaceuticals company famed for its Ozempic and Wegovy weight loss drugs, collapsed after reporting earnings a week ago -- and it's been mostly a downhill slide since. The stock's down again today, bringing cumulative losses to 31%.

This time, you can blame UBS.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Image source: Getty Images.

What UBS says about Novo Nordisk

UBS analyst Matthew Weston removed his buy rating on Novo Nordisk stock this morning, downgrading the shares to neutral and setting a price target of about $52.77, as Street Insider reports. In last week's earnings report, you see, Novo dismissed worries that competition from drug compounding firms, making and selling cheaper versions of Ozempic under their own names, is a significant threat from its business -- but UBS begs to differ.

"Following expert channel checks, we expect GLP1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy," warned Weston. At the same time, the analyst says Novo is continuing to lose market share to rival Eli Lilly (NYSE: LLY) and its own weight loss drugs such as Mounjaro.

Is Novo Nordisk stock a sell?

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo Nordisk stock currently costs less than 14 times earnings.

Although Weston warns that sales growth is slowing to perhaps 6% in the second half of the year from 18% in the first half, that still averages out to about a 12% annual growth rate -- perhaps not explosive, but still respectable. And between the growth rate and the 3.3% dividend, we're looking at a total return of more than 15% on this stock, which makes a 14 P/E ratio look cheap.

Despite (or even because of?) the falling share price, I'd still be a buyer of Novo Nordisk stock.

Should you invest $1,000 in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,103,313!*

Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of August 4, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.